A radical addition and cyclization relay promoted by Mn(OAc)3⋅2H2O: Synthesis of 1,2-oxaphospholoindoles and mechanistic study
作者:Meng-Meng Xu、Lu-Yao Kou、Xiao-Guang Bao、Xiao-Ping Xu、Shun-Jun Ji
DOI:10.1016/j.cclet.2021.02.001
日期:2021.6
Novel and efficient Mn(OAc)3⋅2H2O promoted radical addition-[4 + 1] cyclization relay of 3-indolymethanols and phosphites was disclosed, which afforded 1,2-oxaphospholoindole derivatives in moderate to good yields. Based on the experimental and computational studies, a mechanism involving radical addition and intramolecular cyclization cascade was proposed.
Cascade Reaction to Selectively Synthesize Multifunctional Indole Derivatives by Ir
<sup>III</sup>
‐Catalyzed C−H Activation
作者:Xin‐Yue Chai、Hui‐Bei Xu、Lin Dong
DOI:10.1002/chem.202101602
日期:2021.9.15
way to synthesize with high selectivity a variety of functionalized indoles with potent biological properties has been developed. Notably, 2,4-dialkynyl indole products were obtained by direct double C−H bond alkynylation, whereas alkynyl at the C4 position could convert to carbonyl to generate 2-alkynyl-3,4-diacetyl indoles fast and effectively. Additionally, a one-pot relay catalytic reaction led to
Feasible selective synthesis of 3-Acetylindoles and 3-Acetoacetylindoles from β-ethylthio-β-indoly α, β-unsaturated ketones
作者:Wen-Ju Wang、Hai-Feng Yu
DOI:10.1080/00397911.2018.1555851
日期:2019.2.1
Abstract An efficient and selective synthesis of 3-acetyl free(N-H)/N-substituded indoles and 3-acetoacetyl free(N-H)/N-substituded indoles has been developed via the hydrolysis reaction of β-ethylthio-β-indoly α, β-unsaturatedketones in the presence of 3 equivalent of NaOH and 5 mol% of H2SO4, respectively. The procedure features easy operation, excellent yields, and high selectivity, compatibility
Phosphonate Compounds for Treatment of Complement Mediated Disorders
申请人:Achillion Pharmaceuticals, Inc.
公开号:US20150239921A1
公开(公告)日:2015-08-27
Compounds, methods of use, and processes for making inhibitors of complement factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof wherein R
12
or R
13
on the A group is a phosphonate (R
32
) are provided. The inhibitors described herein target factor D and inhibit or regulate the complement cascade at an early and essential point in the alternative complement pathway, and reduce factor D's ability to modulate the classical and lectin complement pathways. The inhibitors of factor D described herein are capable of reducing the excessive activation of complement, which has been linked to certain autoimmune, inflammatory, and neurodegenerative diseases, as well as ischemia-reperfusion injury and cancer.